Galapagos increases share capital through warrant exercises
(Thomson Reuters ONE) -
Mechelen, Belgium; 1 April 2016, 22.00 CET - Galapagos NV (Euronext & NASDAQ:
GLPG) announces a share capital increase arising from warrant exercises.
Galapagos issued 131,695 new ordinary shares on 1 April 2016, for a total
capital increase (including issuance premium) of ?1,409,307.45.
Pursuant to the rules of the warrant exercise program of Galapagos' Executive
Committee adopted in 2013, Executive Committee members automatically are
committed to exercise a minimum number of warrants, subject to certain
conditions. Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants; two
other Executive Committee members exercised an aggregate number of 5,000
warrants. In addition to Onno van de Stolpe, three other Board members
exercised an aggregate of 45,470 warrants. Raj Parekh and Harrold van Barlingen
exercised warrants to hold them as shares, increasing their shareholdings to
31,250 and 15,620 shares, respectively.
In accordance with Belgian transparency legislation[1], Galapagos notes that its
total share capital currently amounts to ?248,632,657.08; the total number of
securities conferring voting rights is 45,968,738, which is also the total
number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 3,152,997, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises three Phase 2, three Phase 1,
five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-
selective inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group, including fee-
for-service subsidiary Fidelta, has approximately 440 employees, operating from
its Mechelen, Belgium headquarters and facilities in The Netherlands, France,
and Croatia. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Communications Director Communications
Tel: +1 781 460 1784 Tel:
+31 6 53 591 999
E-mail: ir(at)glpg.com E-mail:
communications(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements. Galapagos cautions the
reader that forward-looking statements are not guarantees of future
performance. Forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results, financial
condition and liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions and liquidity, performance or achievements expressed or
implied by such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the development of
the industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. A list and description of these risks, uncertainties and other risks
can be found in Galapagos' Securities and Exchange Commission (SEC) filings and
reports, including in Galapagos' most recent annual report on Form 20 F filed
with the SEC and other filings and reports filed by Galapagos with the SEC.
Given these uncertainties, the reader is advised not to place any undue reliance
on such forward-looking statements. These forward-looking statements speak only
as of the date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based or that
may affect the likelihood that actual results will differ from those set forth
in the forward-looking statements, unless specifically required by law or
regulation.
--------------------------------------------------------------------------------
[1]Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers
whose shares are admitted to trading on a regulated market
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1999857]
Unternehmensinformation / Kurzprofil:
Datum: 01.04.2016 - 22:01 Uhr
Sprache: Deutsch
News-ID 461395
Anzahl Zeichen: 6133
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos increases share capital through warrant exercises"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
